Black Rock Inc. Graphite Bio, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$2.24 - $2.66 $99,832 - $118,550	-44,568 Reduced 2.47%	1,760,019 $4.61 Million
Q3 2023 Nov 13, 2023	BUY	$2.18 - $2.77 $206,607 - $262,523	94,774 Added 5.54%	1,804,587 $4.48 Million
Q2 2023 Aug 11, 2023	BUY	$2.47 - $3.38 $2.97 Million - $4.07 Million	1,202,954 Added 237.34%	1,709,813 $4.45 Million
Q1 2023 May 12, 2023	SELL	$1.85 - $3.21 $25,404 - $44,079	-13,732 Reduced 2.64%	506,859 $1.24 Million
Q4 2022 Feb 13, 2023	BUY	$2.82 - $3.59 $106,099 - $135,070	37,624 Added 7.79%	520,591 $1.73 Million
Q3 2022 Nov 14, 2022	SELL	$2.82 - $4.24 $14,215 - $21,373	-5,041 Reduced 1.03%	482,967 $1.53 Million
Q2 2022 Aug 12, 2022	SELL	$2.14 - $5.23 $2.58 Million - $6.31 Million	-1,206,498 Reduced 71.2%	488,008 $1.34 Million
Q1 2022 May 12, 2022	BUY	$5.1 - $13.06 $2.46 Million - $6.3 Million	482,238 Added 39.78%	1,694,506 $8.64 Million
Q4 2021 Feb 10, 2022	BUY	$8.41 - $16.71 $2.21 Million - $4.38 Million	262,354 Added 27.62%	1,212,268 $15.1 Million
Q3 2021 Nov 09, 2021	BUY	$15.81 - $28.39 $13.4 Million - $24 Million	846,333 Added 817.07%	949,914 $15.6 Million
Q2 2021 Aug 11, 2021	BUY	$18.5 - $30.73 $1.92 Million - $3.18 Million	103,581 New	103,581 $3.18 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.